Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.

Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J

Open source

DOI: 10.1136/rmdopen-2020-001395
Published: 2020 Oct
Container: RMD open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/rmdopen-2020-001395,
  title = {Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.},
  author = {Cohen SB and Tanaka Y and Mariette X and Curtis JR and Lee EB and Nash P and Winthrop KL and Charles-Schoeman C and Wang L and Chen C and Kwok K and Biswas P and Shapiro A and Madsen A and Wollenhaupt J},
  year = {2020},
  journal = {RMD open},
  doi = {10.1136/rmdopen-2020-001395},
  url = {https://doi.org/10.1136/rmdopen-2020-001395}
}

RIS

TY  - JOUR
TI  - Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
AU  - Cohen SB
AU  - Tanaka Y
AU  - Mariette X
AU  - Curtis JR
AU  - Lee EB
AU  - Nash P
AU  - Winthrop KL
AU  - Charles-Schoeman C
AU  - Wang L
AU  - Chen C
AU  - Kwok K
AU  - Biswas P
AU  - Shapiro A
AU  - Madsen A
AU  - Wollenhaupt J
PY  - 2020
JO  - RMD open
DO  - 10.1136/rmdopen-2020-001395
UR  - https://doi.org/10.1136/rmdopen-2020-001395
ER  -

APA

SB, C., Y, T., X, M., JR, C., EB, L., P, N., KL, W., C, C., L, W., C, C., K, K., P, B., A, S., A, M., & J, W. (2020). Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.. RMD open. https://doi.org/10.1136/rmdopen-2020-001395

Source records

pubmed · retrieved 2026-09-26T18:00:09.482Z